brf2 Antibody

What is BRF2 and what cellular functions does it regulate?

BRF2 (Transcription factor IIIB 50 kDa subunit) functions as a general activator of RNA polymerase III transcription. It is specifically required for RNA polymerase III transcription of genes with promoter elements located upstream of initiation sites . Unlike its counterpart BRF1, BRF2 does not form stable complexes with TATA-binding protein, allowing for more dynamic regulation of transcription . This unique characteristic enables precise control of gene expression, particularly in cellular processes requiring timely synthesis of small nuclear RNAs, which are essential for cell growth and differentiation .

Additionally, BRF2 plays a significant role in cellular response to oxidative stress. Research has demonstrated that BRF2 functions as an activator in the absence of oxidative stress but down-regulates expression of target genes when oxidative stress occurs . Interestingly, overexpression of BRF2 has been shown to protect cells against apoptosis in response to oxidative stress, suggesting a potential protective mechanism in certain contexts .

What types of BRF2 antibodies are available for research applications?

Several types of BRF2 antibodies are available for research applications, each with specific characteristics suitable for different experimental approaches. The mouse monoclonal BRF2 antibody (C-8) is an IgG2a kappa light chain antibody that detects BRF2 protein from mouse, rat, and human origins . This antibody is available in both non-conjugated forms and various conjugated formats including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor conjugates .

Researchers can also utilize goat polyclonal BRF2 antibodies, which are suitable for western blotting with human samples . For plant research, custom antibodies have been developed against the C-terminal fragment of BRF2 (amino acids 361-604) . When selecting the appropriate BRF2 antibody, researchers should consider species reactivity, application compatibility, and whether monoclonal specificity or polyclonal broad epitope recognition better serves their experimental needs.

How do I verify the specificity of a BRF2 antibody before using it in my experiments?

Verifying antibody specificity is critical for ensuring reliable experimental results. For BRF2 antibody validation, implement a multi-step approach beginning with positive and negative control samples. Use cell lines or tissues known to express high levels of BRF2 (such as lung cancer cell lines A549 and H292) as positive controls and those with low or no expression (such as normal human lung epithelial BEAS-2B cells) as negative controls .

Perform western blotting to confirm that the antibody detects a protein of the expected molecular weight for BRF2. Additionally, conduct siRNA knockdown experiments by transfecting cells with BRF2-specific siRNA (example sequence: 5′-GGUGGGAAAUAAUUCCUUATT-3′) and confirming reduced signal in immunoblotting or immunofluorescence assays compared to negative control siRNA (example sequence: 5′-UUCUCCGAACGUGUCACGUTT-3′) .

For immunohistochemistry or immunofluorescence applications, include peptide competition assays where pre-incubation of the antibody with the immunizing peptide should abolish or significantly reduce the signal. Cross-reactivity with other BRF family members (BRF1, BRF3) should also be assessed, particularly in experimental systems where multiple BRF proteins are expressed .

What are the optimal protocols for using BRF2 antibody in Western blotting?

For optimal western blotting using BRF2 antibody, begin with proper sample preparation. When working with cell lysates, harvest cells at 70-80% confluence and lyse them in a buffer containing protease inhibitors to prevent protein degradation. For tissue samples, homogenize in an appropriate lysis buffer immediately after collection. Load 20-40 μg of total protein per lane after determining protein concentration using a standard assay.

Transfer proteins to a PVDF or nitrocellulose membrane and block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature. Incubate the membrane overnight at 4°C with primary BRF2 antibody at the recommended dilution (typically 1:500 to 1:1,000 for polyclonal antibodies) . After washing with TBST, incubate with an appropriate HRP-conjugated secondary antibody, such as goat anti-rabbit IgG H&L (1:2,000) for 1-2 hours at room temperature .

For enhanced sensitivity, consider using chemiluminescent detection with digital imaging systems. When probing for multiple proteins, either use separate blots or carefully strip and reprobe the membrane, acknowledging that stripping can reduce protein retention. Always include appropriate loading controls such as β-actin or HISTONE 3 .

How should I optimize immunofluorescence staining with BRF2 antibody?

For immunofluorescence staining with BRF2 antibody, begin by growing cells (approximately 2×10^4/ml) on coverslips until they reach 50-70% confluence. Fix cells with 4% formaldehyde in warm PBS for 15 minutes at room temperature, which preserves cellular architecture while maintaining antigen accessibility . After fixation, rinse cells in PBS for 5 minutes to remove excess fixative.

Permeabilize cells with 0.1-0.5% Triton X-100 in PBS for 5-10 minutes, which allows antibody access to intracellular antigens. Block with immunostaining blocking buffer at 37°C for 60 minutes to reduce non-specific binding. Incubate with primary BRF2 antibody at the appropriate dilution (1:500 has been successfully used with anti-BRF2 antibody) overnight at 4°C . After washing three times with PBS (5 minutes each), incubate with fluorochrome-conjugated secondary antibody for 1 hour at room temperature protected from light.

For nuclear visualization, counterstain with DAPI or Hoechst. Mount slides with an anti-fade mounting medium to prevent photobleaching during imaging. When analyzing results, pay particular attention to nuclear localization of BRF2, as it primarily functions in transcriptional regulation, while also documenting any cytoplasmic distribution that may be biologically relevant.

What controls should be included when performing immunohistochemistry with BRF2 antibody?

When performing immunohistochemistry with BRF2 antibody, include multiple controls to ensure result validity. Always run positive control tissues known to express BRF2, such as lung cancer tissues which have been shown to have high BRF2 expression . Parallel negative controls should include normal tissues with minimal BRF2 expression, such as normal lung tissues .

Procedural controls are equally important. Include a no-primary-antibody control where the section is treated with antibody diluent alone to assess background staining from the secondary antibody system. Additionally, implement an isotype control using a non-specific antibody of the same isotype and concentration as your BRF2 antibody to identify potential Fc receptor binding or other non-specific interactions.

For quantitative assessments, establish a scoring system based on staining intensity and percentage of positive cells. Compare staining patterns between different tissue sections using standardized imaging conditions. When performing antigen retrieval, optimize pH and retrieval time specifically for BRF2, as different epitopes may require different retrieval conditions. Document any differences in staining patterns between tumor and adjacent normal tissues, as these may provide insights into BRF2's role in pathological processes .

How is BRF2 antibody used to study its role in cancer progression?

BRF2 antibody serves as a crucial tool for investigating the role of BRF2 in cancer progression through multiple experimental approaches. Immunohistochemistry with BRF2 antibody allows researchers to compare expression levels between cancer tissues and normal adjacent tissues, revealing that BRF2 protein is substantially upregulated in lung cancer tissues compared to normal lung tissues . This differential expression pattern provides initial evidence of BRF2's potential involvement in cancer development.

Immunofluorescence staining using BRF2 antibody enables cellular-level analysis of expression patterns across various cell types. Studies have demonstrated that marker protein BRF2 is positively expressed in lung cancer cell lines A549 and H292, with particularly high expression in A549 cells, while normal human lung epithelial BEAS-2B cells show minimal expression . These expression patterns can be correlated with cellular phenotypes to understand how BRF2 contributes to transformed cell behavior.

To establish causal relationships between BRF2 and cancer phenotypes, researchers combine BRF2 antibody with gene silencing approaches. After transfecting cells with BRF2 siRNA, western blotting with BRF2 antibody confirms knockdown efficiency before analyzing effects on cell proliferation, apoptosis, migration, and invasion. This integrated approach has revealed that silencing BRF2 promotes cancer cell apoptosis while inhibiting proliferation and migration, supporting BRF2's role as a potential therapeutic target .

What signaling pathways interact with BRF2 in disease contexts?

BRF2 interacts with several critical signaling pathways in disease contexts, particularly in cancer, where these interactions contribute to cellular transformation and disease progression. Western blotting analyses using BRF2 antibody along with antibodies against pathway components have revealed that BRF2 silencing significantly impacts the PI3K/Akt pathway, a major regulator of cell survival and proliferation . Specifically, BRF2 knockdown reduces levels of both total Akt and phosphorylated Akt (p-Akt), suggesting that BRF2 positively regulates this pro-survival pathway in cancer cells .

The apoptotic pathway is also modulated by BRF2, as evidenced by changes in the Bcl-2/Bax ratio following BRF2 silencing. In BRF2-silenced cancer cells, anti-apoptotic Bcl-2 protein levels decrease while pro-apoptotic Bax protein levels increase, explaining the enhanced apoptosis observed in these cells . This indicates that BRF2 normally functions to suppress apoptotic signaling in cancer cells.

BRF2 additionally influences epithelial-mesenchymal transition (EMT) pathways, which are crucial for cancer metastasis. BRF2 silencing increases expression of epithelial marker E-cadherin while decreasing mesenchymal markers N-cadherin and Snail, suggesting that BRF2 promotes EMT in cancer cells . Furthermore, BRF2 silencing reduces epidermal growth factor receptor (EGFR) expression, indicating interaction with growth factor signaling networks that drive proliferation and survival .

How does BRF2 expression correlate with clinical outcomes in cancer patients?

The correlation between BRF2 expression and clinical outcomes in cancer patients presents a compelling area of investigation where BRF2 antibody serves as an essential research tool. Immunohistochemical analysis of lung cancer tissue samples using BRF2 antibody has demonstrated significantly higher BRF2 expression compared to normal adjacent tissues, providing a foundation for clinical correlation studies . This differential expression pattern suggests BRF2 as a potential biomarker for disease state and progression.

Mechanistic studies using BRF2 antibody to monitor protein expression have revealed that BRF2 regulates pathways critical for cancer cell survival, proliferation, and metastasis, including Akt signaling and epithelial-mesenchymal transition . These molecular insights help explain clinical observations where elevated BRF2 expression correlates with aggressive disease characteristics. The pronounced effects of BRF2 silencing on cancer cell apoptosis, proliferation inhibition, and reduced migration capacity in experimental models suggest that high BRF2 expression in patient tumors likely promotes more aggressive disease behavior .

Research utilizing BRF2 antibody has revealed that BRF2 overexpression protects cells against apoptosis during oxidative stress, which may contribute to cancer cell survival under adverse conditions within the tumor microenvironment . This protective mechanism potentially enables cancer cells to withstand therapy-induced stress, suggesting that BRF2 expression levels might predict treatment resistance. These findings collectively indicate that BRF2 represents not only a potential prognostic biomarker but also a promising therapeutic target in cancer treatment strategies.

How can BRF2 antibody be used in chromatin immunoprecipitation (ChIP) studies?

Chromatin immunoprecipitation (ChIP) with BRF2 antibody allows researchers to identify genomic regions where BRF2 binds, providing crucial insights into its transcriptional regulatory function. For effective BRF2 ChIP experiments, begin with proper crosslinking of protein-DNA complexes using 1% formaldehyde for 10-15 minutes at room temperature. After quenching with glycine, lyse cells and sonicate chromatin to fragments of approximately 200-500 bp, with sonication conditions optimized for your specific cell type.

Immunoprecipitate chromatin fragments using a ChIP-validated BRF2 antibody, ideally at a concentration of 2-5 μg per reaction, incubating overnight at 4°C with rotation. Include appropriate negative controls such as IgG from the same species as the BRF2 antibody, and positive controls targeting known abundant transcription factors or histone modifications. After washing to remove non-specific binding, reverse crosslinks and purify DNA for subsequent analysis.

For downstream analysis, consider both targeted approaches (qPCR for known or suspected target promoters, particularly those with RNA polymerase III promoter elements) and genome-wide methods such as ChIP-seq. When analyzing ChIP-seq data, focus on identifying enrichment at promoters of genes transcribed by RNA polymerase III, especially those with upstream promoter elements, as BRF2 is exclusively required for RNA polymerase III transcription of genes with such promoter architecture . Correlation with transcriptome data can provide functional validation of BRF2 binding sites.

What approaches can be used to study BRF2 protein-protein interactions?

Several sophisticated approaches can be employed to study BRF2 protein-protein interactions, each with specific advantages. Co-immunoprecipitation (Co-IP) using BRF2 antibody represents a foundational method to identify endogenous protein complexes containing BRF2. For effective Co-IP, lyse cells under non-denaturing conditions to preserve protein-protein interactions, pre-clear lysates with protein A/G beads, and incubate with BRF2 antibody overnight at 4°C. After washing, analyze precipitated complexes by western blotting for suspected interaction partners or by mass spectrometry for unbiased discovery.

For validation of direct interactions and domain mapping, consider implementing in vitro binding assays using recombinant BRF2 protein. Proximity ligation assay (PLA) offers an alternative approach for visualizing protein interactions in situ, requiring antibodies against both BRF2 and its suspected interaction partner from different species. When PLA probes bind to the primary antibodies in close proximity (<40 nm), they generate fluorescent signals that can be quantified to assess interaction strength.

Bimolecular fluorescence complementation (BiFC) provides another option for visualizing interactions in living cells. This technique involves fusing potential interaction partners to complementary fragments of a fluorescent protein (e.g., YFP). When BRF2 interacts with its partner, the fragments come together to reconstitute functional fluorescence. Focus particularly on interactions with RNA polymerase III components and other transcription factors, as BRF2's primary function involves recruitment of RNA polymerase III to specific promoters .

How should I interpret contradictory results from different BRF2 antibodies?

Contradictory results from different BRF2 antibodies require systematic troubleshooting and careful interpretation. Begin by conducting a comprehensive antibody validation comparison. Examine the immunogens used to generate each antibody - those recognizing different epitopes within BRF2 may yield different results, particularly if certain domains are masked by protein-protein interactions or post-translational modifications in your experimental system.

Test each antibody's specificity through knockdown or knockout validation experiments. Transfect cells with BRF2-specific siRNA and assess signal reduction with each antibody. A genuine BRF2 antibody should show substantially decreased signal in knockdown samples compared to controls . For antibodies passing this validation, differences in results may reflect detection of different BRF2 isoforms, post-translationally modified variants, or BRF2 in different protein complexes.

Consider technical factors that might explain discrepancies. Different antibodies may require specific fixation methods, epitope retrieval procedures, or blocking reagents. Optimization for each antibody might be necessary, following manufacturer recommendations. Additionally, evaluate cross-reactivity with other BRF family members (BRF1, BRF3) which share sequence homology with BRF2 . When reporting results, clearly specify which antibody was used and acknowledge any limitations in interpretation. If possible, rely on multiple antibodies recognizing different epitopes to strengthen confidence in your findings.

Why might I observe non-specific binding with BRF2 antibody in immunohistochemistry?

Non-specific binding with BRF2 antibody in immunohistochemistry can arise from multiple sources that require methodical troubleshooting. Endogenous peroxidase activity in tissues, particularly those rich in blood cells or mitochondria, may cause background staining. Pretreat sections with 0.3-3% hydrogen peroxide in methanol for 20 minutes at room temperature to quench this activity before antibody incubation . Inadequate blocking represents another common cause of non-specific binding; optimize by testing different blocking solutions (5-10% normal serum from the same species as the secondary antibody, BSA, or commercial blocking reagents) and extending blocking time to 60 minutes or longer .

Cross-reactivity with related proteins, particularly other BRF family members like BRF1 and BRF3 which share sequence homology with BRF2, may also contribute to non-specific signals . To mitigate this, consider using monoclonal antibodies with validated specificity or perform peptide competition assays. The fixation method significantly impacts epitope accessibility; if using formalin-fixed tissues, optimize antigen retrieval by testing different buffers (citrate pH 6.0 vs. EDTA pH 9.0) and retrieval times.

Secondary antibody cross-reactivity can produce false positives, particularly in tissues with high endogenous immunoglobulin content. Include a no-primary-antibody control and consider using secondary antibodies pre-adsorbed against tissue species proteins. Finally, excessive antibody concentration often increases background; perform titration experiments to determine the minimum antibody concentration that yields specific signal while minimizing background.

What factors affect the sensitivity of BRF2 detection in western blotting?

Multiple factors influence BRF2 detection sensitivity in western blotting, requiring careful optimization for robust results. Sample preparation significantly impacts detection - incomplete cell lysis, protein degradation, or inefficient extraction of nuclear proteins (where BRF2 is predominantly located) can reduce signal. Use stringent lysis buffers containing detergents suitable for nuclear proteins, supplemented with protease inhibitors, and maintain samples at 4°C throughout processing to preserve protein integrity.

Protein loading amount requires optimization; insufficient protein results in weak or undetectable signals, while excessive loading causes smearing and high background. Start with 20-40 μg total protein per lane, adjusting based on observed results. Transfer efficiency critically affects detection sensitivity - incomplete transfer of higher molecular weight proteins is common with standard protocols. For BRF2 detection, consider using wet transfer systems with methanol-containing buffers and extending transfer time or reducing voltage for larger proteins.

Antibody selection and dilution directly impact sensitivity and specificity. Primary antibody dilutions typically range from 1:500 to 1:1,000 for polyclonal BRF2 antibodies , but optimal concentration should be determined empirically for each application. Extended primary antibody incubation (overnight at 4°C) generally improves signal strength. Detection system choice is equally important - enhanced chemiluminescence (ECL) systems offer good sensitivity, while fluorescent secondary antibodies provide superior linearity for quantitative analyses. For particularly challenging detections, consider signal amplification systems or highly sensitive substrate formulations.

How can I optimize BRF2 antibody-based assays for detecting low abundance targets?

Detecting low-abundance BRF2 requires specialized optimization strategies across multiple experimental platforms. For western blotting applications, implement protein enrichment techniques before analysis. Since BRF2 is predominantly nuclear, perform subcellular fractionation to isolate nuclear extracts, effectively concentrating BRF2 relative to whole cell lysates . Consider immunoprecipitation with BRF2 antibody prior to western blotting, which can significantly enrich the target protein from complex samples.

Signal amplification systems substantially enhance detection sensitivity. For western blotting, utilize high-sensitivity chemiluminescent substrates with extended exposure times or biotin-streptavidin amplification systems. In immunohistochemistry and immunofluorescence, implement tyramide signal amplification (TSA), which can increase sensitivity by 10-100 fold compared to conventional detection methods. This technique involves HRP-catalyzed deposition of fluorophore-labeled tyramide, creating multiple detectable molecules for each antibody binding event.

For particularly challenging samples, consider alternative detection platforms. Proximity ligation assay (PLA) offers single-molecule sensitivity by generating amplifiable DNA circles when two antibodies bind in close proximity. This approach can detect protein-protein interactions involving BRF2 even when expression levels are below the detection threshold of conventional methods. Digital PCR-based protein detection methods like Proximity Extension Assay (PEA) provide another ultra-sensitive alternative, combining the specificity of antibody recognition with the amplification power of PCR.

How does BRF2 function differ across experimental model systems?

BRF2 function shows notable differences across experimental model systems, reflecting its context-dependent roles in transcriptional regulation. In human cellular models, BRF2 functions as an essential component of RNA polymerase III transcription machinery, specifically required for transcription of genes with promoter elements upstream of initiation sites . This specialized function distinguishes BRF2 from other transcription factors and highlights its importance in precise regulation of gene expression programs in mammalian cells.

Intriguingly, research in plant models has revealed divergent functions for BRF2. In Arabidopsis, BRF2 acts as a negative regulator of thermotolerance, with mutations in BRF2 increasing heat stress resistance . This contrasts with its role in human cells, where BRF2 overexpression protects against oxidative stress-induced apoptosis . The opposing effects observed in different organisms suggest that BRF2 has evolved distinct regulatory mechanisms across eukaryotic lineages while maintaining its core function in transcriptional control.

The molecular interactions of BRF2 also vary between experimental systems. In human cancer cells, BRF2 interacts with signaling networks including PI3K/Akt and epithelial-mesenchymal transition pathways , while in plant systems, BRF genes show complex genetic interactions where double mutations of BRF1 and BRF2 lead to sterility . These system-specific interactions underscore the importance of validating BRF2 function in the particular experimental model being studied, rather than extrapolating findings across distant evolutionary lineages.

What is the relationship between BRF2 function and oxidative stress response?

BRF2 exhibits a complex relationship with oxidative stress response mechanisms, functioning as both a sensor and regulator of cellular redox status. Under normal conditions, BRF2 serves as a transcriptional activator, but during oxidative stress, it down-regulates expression of its target genes . This dynamic regulatory switch enables cells to modulate gene expression programs in response to changing redox environments, adapting transcriptional output to cellular needs.

Mechanistically, BRF2 overexpression confers protection against oxidative stress-induced apoptosis, suggesting it plays a cytoprotective role during redox imbalance . This protective function may be particularly relevant in cancer cells, which often experience heightened oxidative stress due to metabolic alterations and must develop adaptive mechanisms to survive. The ability of BRF2 to promote survival under oxidative conditions potentially contributes to its association with aggressive cancer phenotypes and poor clinical outcomes.

The relationship between BRF2 and oxidative stress extends to its interactions with signaling pathways known to respond to redox status. For instance, the PI3K/Akt pathway, which is modulated by BRF2 in cancer cells , is sensitive to oxidative stress and plays a key role in cell survival under adverse conditions. This suggests that BRF2 may integrate into broader cellular stress response networks, coordinating transcriptional programs with signaling cascades to orchestrate appropriate cellular adaptations to oxidative challenges.

How can BRF2 antibody be used in high-throughput screening applications?

BRF2 antibody can be effectively integrated into high-throughput screening (HTS) platforms to identify modulators of BRF2 expression or activity across large compound libraries or genetic perturbation screens. Cell-based ELISA represents one adaptable format for BRF2 HTS applications. Cells can be cultured in 96- or 384-well plates, treated with compound libraries or siRNA/sgRNA, then fixed and probed with BRF2 antibody followed by HRP-conjugated secondary antibody . This approach permits quantitative assessment of BRF2 protein levels in response to thousands of perturbations, enabling identification of both positive and negative regulators.

Automated immunofluorescence microscopy (high-content screening) offers enhanced capabilities by simultaneously measuring BRF2 expression levels, subcellular localization, and associated phenotypic changes. By combining BRF2 antibody with markers for cellular compartments, cell cycle status, or apoptosis, researchers can correlate changes in BRF2 with specific cellular outcomes. This multiplexed approach is particularly valuable for identifying compounds that modulate BRF2 function rather than simply altering expression levels.

For tracking BRF2 activity rather than expression, reporter-based systems can be developed where BRF2-dependent promoters drive expression of luminescent or fluorescent proteins. These systems can be calibrated using validated BRF2 antibodies and then deployed in high-throughput formats. When implementing any BRF2 antibody-based HTS platform, include appropriate positive controls (known BRF2 modulators) and negative controls (non-targeting compounds or constructs) on each plate to normalize for inter-plate variability and establish statistical thresholds for hit identification.